Takeda to buy back more shares
This article was originally published in Scrip
Executive Summary
The board of Takedahas approved the purchase of up to a further nine million of the company's own shares for a maximum of ¥50 billion ($472.6 million). The programme adds to the ¥100 billion worth of shares, around 2% of the Japanese firm's issued total, which were acquired earlier this year and cancelled in June. Takeda and several other Japanese pharma majors have been implementing buybacks to improve shareholder returns and guard against possible hostile takeovers.